Tags

Type your tag names separated by a space and hit enter

A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up.
J Med Assoc Thai 1995; 78(6):298-304JM

Abstract

Tuberculosis is still a major public health threat in Thailand. The introduction of a short course of chemotherapy at national level might help reduce the magnitude of the problem. In order to assess the efficacy and toleration of two different regimens of chemotherapy under field conditions, a comparative clinically controlled trial was conducted at the Central Chest Hospital in Nonthaburi, Thailand. From January 1988 to August 1990, 199, newly diagnosed, untreated, sputum positive tuberculosis patients were allocated randomly to two treatment groups; in Group A, 97 patients received Rifater daily for the first 2 months, followed by Rifinah daily for 4 months (2 Rifater/4 Rifinah). In Group B, 102 patients received Rifater supplemented by ethambutol daily for the first 2 months followed by thiacetazone and isoniazid daily for 6 months (2 Rifater EMB/6 HT.) Treatment results were very satisfactory in both groups. At the end of treatment conversion rates were 100 per cent in Group A, and 99 per cent in Group B. After a period of 36 months following completion of treatment, relapse rates of 3 per cent for Group A and 4 per cent for Group B were observed. Adverse reactions were minimal in both groups, but acne formation and gastrointestinal symptoms were noticed more in Group B, suggestive of thiacetazone side effects. This study shows that, the 6-months regimen is as effective as the 8-months regimen. Although the 8-months regimen is cheaper, it causes more gastrointestinal disturbance and skin reaction which might led to less patient compliance and result in a lower cure rate.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Central Chest Hospital, Department of Communicable Diseases Control, Ministry of Public Health, Nonthaburi, Thailand.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7561554

Citation

Punnotok, J, et al. "A Comparison of Two Short Course Tuberculosis Chemotherapy Regimens, Both Using Rifater During an Intensive Phase, With a 3 Year Follow-up." Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, vol. 78, no. 6, 1995, pp. 298-304.
Punnotok J, Pumprueg U, Chakorn T. A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. J Med Assoc Thai. 1995;78(6):298-304.
Punnotok, J., Pumprueg, U., & Chakorn, T. (1995). A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 78(6), pp. 298-304.
Punnotok J, Pumprueg U, Chakorn T. A Comparison of Two Short Course Tuberculosis Chemotherapy Regimens, Both Using Rifater During an Intensive Phase, With a 3 Year Follow-up. J Med Assoc Thai. 1995;78(6):298-304. PubMed PMID: 7561554.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of two short course tuberculosis chemotherapy regimens, both using Rifater during an intensive phase, with a 3 year follow-up. AU - Punnotok,J, AU - Pumprueg,U, AU - Chakorn,T, PY - 1995/6/1/pubmed PY - 1995/6/1/medline PY - 1995/6/1/entrez SP - 298 EP - 304 JF - Journal of the Medical Association of Thailand = Chotmaihet thangphaet JO - J Med Assoc Thai VL - 78 IS - 6 N2 - Tuberculosis is still a major public health threat in Thailand. The introduction of a short course of chemotherapy at national level might help reduce the magnitude of the problem. In order to assess the efficacy and toleration of two different regimens of chemotherapy under field conditions, a comparative clinically controlled trial was conducted at the Central Chest Hospital in Nonthaburi, Thailand. From January 1988 to August 1990, 199, newly diagnosed, untreated, sputum positive tuberculosis patients were allocated randomly to two treatment groups; in Group A, 97 patients received Rifater daily for the first 2 months, followed by Rifinah daily for 4 months (2 Rifater/4 Rifinah). In Group B, 102 patients received Rifater supplemented by ethambutol daily for the first 2 months followed by thiacetazone and isoniazid daily for 6 months (2 Rifater EMB/6 HT.) Treatment results were very satisfactory in both groups. At the end of treatment conversion rates were 100 per cent in Group A, and 99 per cent in Group B. After a period of 36 months following completion of treatment, relapse rates of 3 per cent for Group A and 4 per cent for Group B were observed. Adverse reactions were minimal in both groups, but acne formation and gastrointestinal symptoms were noticed more in Group B, suggestive of thiacetazone side effects. This study shows that, the 6-months regimen is as effective as the 8-months regimen. Although the 8-months regimen is cheaper, it causes more gastrointestinal disturbance and skin reaction which might led to less patient compliance and result in a lower cure rate.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0125-2208 UR - https://www.unboundmedicine.com/medline/citation/7561554/A_comparison_of_two_short_course_tuberculosis_chemotherapy_regimens_both_using_Rifater_during_an_intensive_phase_with_a_3_year_follow_up_ L2 - http://www.diseaseinfosearch.org/result/7252 DB - PRIME DP - Unbound Medicine ER -